Last updated: October 15, 2026
Povidone K90 is a high-molecular-weight pharmaceutical excipient used mainly as a tablet binder, film former, suspension aid and viscosity modifier. Its market is driven by generic oral solid-dose manufacturing, high-dose formulations and demand for improved granulation performance. The product has limited standalone financial disclosure because major suppliers report it within broader pharmaceutical excipient or specialty ingredients portfolios.
The market outlook is moderately positive. Volume growth should track tablet production and generic-drug expansion, while revenue growth will depend on pharmaceutical-grade qualification, supply security, raw-material costs and the premium attached to high-purity, low-residual-monomer grades. Patent exclusivity is not the main commercial barrier. Manufacturing qualification, regulatory documentation and customer switching costs are more important.
What is povidone K90 and how is it used in pharmaceuticals?
Povidone K90 is a high-molecular-weight grade of polyvinylpyrrolidone, also called PVP or povidone. The "K90" designation describes the product's viscosity or K-value range rather than a separate chemical entity. Higher K-values generally indicate higher molecular weight and greater solution viscosity.
| Attribute |
Povidone K90 profile |
| Chemical name |
Polyvinylpyrrolidone |
| Common abbreviation |
PVP |
| Main pharmaceutical role |
Binder, film former, suspending and viscosity-modifying agent |
| Typical dosage-form use |
Tablets, granules, oral powders and selected liquid or topical products |
| Key performance property |
Strong binding and high solution viscosity |
| Regulatory identity |
Compendial excipient, not an active pharmaceutical ingredient |
| Related products |
Povidone K25, K30, K90 and crospovidone |
| Main commercial distinction |
Higher molecular weight than lower-K povidone grades |
K90 is particularly relevant to wet granulation, where it can improve particle cohesion, tablet hardness and granule integrity. It can also be used where a formulation requires a higher-viscosity polymer than K30. Crospovidone should not be treated as an interchangeable substitute. Crospovidone is crosslinked and functions primarily as a tablet disintegrant, while povidone K90 is generally used as a soluble binder or rheology modifier.
BASF markets high-molecular-weight povidone under the Kollidon family. Ashland markets povidone grades under the Plasdone brand. Other regional and global suppliers include JRS Pharma, Boai NKY Pharmaceuticals and selected Chinese and Indian manufacturers, subject to the applicable grade, pharmacopoeial status and customer qualification.
How large is the povidone K90 market?
No major public company reports revenue specifically for povidone K90. Published market estimates usually combine several products, including povidone, crospovidone, copovidone and other pharmaceutical polymers. Standalone K90 revenue therefore cannot be calculated reliably from public filings.
The relevant market is best analyzed through four layers:
- Pharmaceutical-grade povidone.
- High-molecular-weight povidone, including K90.
- Oral solid-dose excipients.
- Specialty pharmaceutical ingredients.
Povidone K90 is a niche within the broader excipient market. Its value per kilogram is higher than commodity-grade industrial PVP because pharmaceutical customers pay for documentation, validated manufacturing, impurity control, batch consistency and regulatory support. Demand is concentrated among tablet manufacturers, generic-drug companies, contract development and manufacturing organizations, and finished-dose producers.
What is driving demand for povidone K90?
Demand is supported by:
- Growth in generic tablets and capsules.
- Expansion of pharmaceutical manufacturing in India, China and Southeast Asia.
- Continued use of wet granulation for poorly flowing or poorly compressible active ingredients.
- Reformulation activity involving solubility, dose uniformity and tablet robustness.
- Growth in contract manufacturing and multi-site supply qualification.
- Demand for excipients with global compendial coverage.
K90 demand is more formulation-specific than K30 demand. The product is not required in every tablet formulation, and formulators may select lower-viscosity povidone, copovidone, hydroxypropyl cellulose or starch-based binders when those materials meet performance requirements.
Who are the leading povidone K90 suppliers?
The competitive market has a small group of multinational suppliers and a broader regional manufacturing base.
| Supplier |
Relevant brand or position |
Competitive advantage |
| BASF |
Kollidon povidone portfolio |
Global regulatory support, broad excipient range and established pharmaceutical relationships |
| Ashland |
Plasdone povidone portfolio |
Pharmaceutical excipient specialization and formulation support |
| JRS Pharma |
Pharmaceutical excipients and functional ingredients |
European manufacturing base and formulation-focused portfolio |
| Boai NKY Pharmaceuticals |
Povidone and related pharmaceutical excipients |
Large Asian manufacturing footprint and cost competitiveness |
| Regional Chinese and Indian producers |
Povidone and polymer grades |
Price, local availability and regional customer access |
Supplier competition is based on more than quoted price. Buyers evaluate residual N-vinylpyrrolidone, peroxide and other impurity controls, particle-size distribution, microbial specifications, batch-to-batch viscosity, packaging, change-control procedures and audit history.
A supplier with a lower nominal price can remain commercially unattractive if a customer must repeat formulation studies, stability work, process validation or regulatory filings. This creates qualification-based switching costs.
What determines povidone K90 pricing?
Pricing is influenced by raw materials, production scale, grade certification and supply security. The main upstream material is N-vinylpyrrolidone, with costs affected by energy, chemical feedstocks, plant utilization and environmental-compliance requirements.
The price structure generally includes:
- Polymerization and purification costs.
- Pharmaceutical-grade quality-control costs.
- Testing for residual monomer and other impurities.
- Documentation and regulatory support.
- Packaging and storage.
- Distributor margins.
- Customer-specific qualification and supply commitments.
K90 is more expensive to manufacture and handle than lower-viscosity grades because high molecular weight increases viscosity and complicates processing. The product can also require tighter control of dissolution, filtration and batch consistency.
Pricing pressure is strongest in standardized generic formulations where multiple grades have already been qualified. Pricing power is stronger when K90 is embedded in a technically sensitive formulation or when a customer has limited approved suppliers.
What is the financial trajectory for the povidone K90 market?
The financial trajectory is likely to show low- to mid-single-digit underlying volume growth in established pharmaceutical markets, with stronger growth in emerging manufacturing regions. Revenue growth can exceed volume growth when customers move toward higher-purity grades, dual sourcing, smaller validated batches or enhanced regulatory documentation.
The main financial scenarios are:
| Scenario |
Market condition |
Financial effect |
| Base case |
Steady generic-tablet growth and stable supplier competition |
Moderate volume growth with limited price expansion |
| Upside case |
Higher use in difficult-to-process APIs, stronger Asian manufacturing demand and supply qualification |
Above-market growth for qualified suppliers |
| Downside case |
Formulation substitution, excess capacity or raw-material deflation |
Flat or declining realized pricing |
| Margin pressure case |
Energy, labor or compliance costs rise faster than contract repricing |
Lower supplier margins despite stable demand |
Public-company financial statements do not provide direct K90 revenue exposure. BASF reports pharmaceutical excipients within broader business units, while Ashland reports pharmaceutical ingredients within its Life Sciences activities. Their reported results can indicate portfolio conditions but cannot be used to calculate K90 sales or margins specifically (Ashland, 2024; BASF, 2024).
For investors and licensors, K90 should be assessed as a recurring specialty-materials business rather than as a patent-protected pharmaceutical asset. Customer retention, production reliability and quality-system performance are more relevant valuation factors than nominal market share alone.
What regulatory status does povidone K90 have?
Povidone is recognized in major pharmaceutical compendia, including the United States Pharmacopeia-National Formulary and European Pharmacopoeia, subject to the applicable monograph and grade requirements (United States Pharmacopeial Convention, 2024; European Directorate for the Quality of Medicines & HealthCare, 2024).
The FDA Inactive Ingredient Database lists povidone in approved drug products across dosage forms and routes, although the database does not create blanket approval for every K-value, supplier or formulation (U.S. Food and Drug Administration, 2024).
Regulatory qualification normally requires:
- Certificate of analysis.
- Current Good Manufacturing Practice documentation.
- Residual N-vinylpyrrolidone data.
- Microbial and elemental impurity controls.
- Stability and retest information.
- Change-control commitments.
- Supplier audit and quality agreements.
- Drug Master File or equivalent regulatory support where applicable.
The practical regulatory risk is grade substitution. A change from one K-value or supplier to another may affect viscosity, granulation endpoint, tablet hardness, dissolution and bioequivalence. Finished-dose manufacturers may need formulation comparability or regulatory reporting before implementing the change.
What patents protect povidone K90?
Povidone K90 does not have meaningful current pharmaceutical patent exclusivity comparable to an active drug ingredient. PVP is an established polymer, and the basic chemical composition and common pharmaceutical uses are long-standing technologies.
The relevant IP categories are:
- Manufacturing process know-how.
- Polymerization and purification controls.
- Impurity-reduction methods.
- Particle engineering.
- Grade-specific specifications.
- Trademarks such as Kollidon and Plasdone.
- Customer-specific formulation know-how.
A patent search may identify process or formulation patents that mention povidone, but those patents generally protect a particular manufacturing method or finished dosage form rather than the broad sale of povidone K90.
Are there Paragraph IV challenges or Orange Book listings for povidone K90?
No. Povidone K90 is an excipient, not an FDA-approved active pharmaceutical ingredient. It is not independently listed in the Orange Book, and Paragraph IV certification does not apply to the sale of the excipient itself.
There is also no biosimilar risk specific to K90. Biologic manufacturers may use povidone or related polymers in certain formulations, but biosimilar litigation concerns the biologic product's patents, not an independent exclusivity right in povidone K90.
What manufacturing and IP barriers affect market entry?
Manufacturing entry is possible but not frictionless. A new supplier must establish polymerization control, purification capacity, compendial testing, pharmaceutical quality systems and a reliable regulatory package.
The main barriers are:
- Consistent molecular-weight and viscosity control.
- Low residual N-vinylpyrrolidone.
- Control of peroxide and color formation.
- Microbial and particulate control.
- Scale-up without changing dissolution or binding performance.
- Customer qualification and audit approval.
- Regulatory support across the United States, European Union, India and other markets.
- Supply continuity during plant shutdowns or raw-material disruptions.
The IP barrier is weaker than the quality and qualification barrier. Trademarks and confidential process know-how protect incumbent positioning, but a technically capable producer can compete without licensing a foundational patent.
What litigation and licensing activity affects povidone K90?
There is no well-established Orange Book litigation framework for K90, and public litigation involving the excipient itself is limited compared with litigation involving active drugs, delivery systems or finished formulations.
Commercial relationships are more likely to involve:
- Distribution agreements.
- Technical-service arrangements.
- Long-term supply contracts.
- Dual-sourcing commitments.
- Quality agreements.
- Regulatory-support agreements.
- Private-label or regional manufacturing arrangements.
Licensing revenue is therefore unlikely to be the primary value driver for standard K90. The stronger commercial asset is a qualified supply position with repeat pharmaceutical customers.
How does povidone K90 compare with competing binders?
| Excipient |
Main advantage |
Limitation relative to K90 |
| Povidone K30 |
Broad use and lower viscosity |
May provide less binding or viscosity at the same concentration |
| Copovidone |
Strong binding and improved processing in selected systems |
Different dissolution and formulation behavior |
| Hydroxypropyl cellulose |
Binding and film-forming performance |
May require different process and dissolution optimization |
| Pregelatinized starch |
Cost and availability |
Can have greater batch and moisture sensitivity |
| Hypromellose |
Film formation and controlled-release utility |
Not a direct substitute for all wet-granulation applications |
| Crospovidone |
Rapid disintegration |
Chemically and functionally distinct from soluble K90 |
Formulators usually select among these materials based on API properties, manufacturing process, tablet strength, disintegration, dissolution and regulatory history. K90's strongest position is in applications where higher molecular weight and binding strength justify its processing and cost profile.
What generic launch risks exist for povidone K90?
Generic-drug launch risk is indirect. A generic manufacturer does not face patent expiry for K90 itself, but it may face:
- Supply interruption from a qualified supplier.
- Inability to substitute grades without reformulation.
- Batch variability affecting dissolution or hardness.
- Regulatory delay caused by excipient-source changes.
- Cost increases under fixed-price supply contracts.
- Dependence on a single regional producer.
- Import restrictions or logistics disruption.
For investors, the relevant exposure is the volume of finished-dose products using K90 multiplied by the probability that customers retain the grade after qualification. A supplier with broad customer approval and multiple manufacturing sites has lower revenue volatility than a low-cost producer dependent on spot purchases.
Key Takeaways
- Povidone K90 is a high-molecular-weight PVP excipient used mainly for binding, viscosity modification and film formation.
- Demand is tied to generic tablets, contract manufacturing and pharmaceutical production in emerging markets.
- BASF and Ashland are prominent multinational suppliers, with Asian manufacturers adding price competition.
- Standalone K90 revenue is not disclosed publicly, so precise market-size or supplier-share figures are not reliable.
- Regulatory qualification, impurity control and customer approval are stronger barriers than composition patents.
- K90 has no independent Orange Book listing, Paragraph IV pathway or biosimilar exclusivity.
- Pricing power is strongest in validated formulations with limited approved suppliers.
- The financial outlook is moderately positive, but margin performance will depend on raw-material costs, capacity and supplier qualification.
- Manufacturing know-how, quality systems and supply reliability are the principal strategic assets.
FAQs about povidone K90
Is povidone K90 the same as crospovidone?
No. Povidone K90 is a soluble, high-molecular-weight PVP grade used mainly as a binder or viscosity modifier. Crospovidone is crosslinked PVP used mainly as a tablet disintegrant.
Is povidone K90 interchangeable with povidone K30?
Not automatically. K90 has higher molecular weight and viscosity. Substitution can change granulation, tablet hardness, dissolution and process performance, requiring formulation and regulatory assessment.
Does povidone K90 have an FDA exclusivity period?
No. Povidone K90 is an inactive pharmaceutical ingredient and does not receive drug exclusivity under the Hatch-Waxman framework.
Which industries outside pharmaceuticals buy PVP K90?
Industrial applications include cosmetics, adhesives, coatings, inks and specialty materials. Pharmaceutical-grade K90 is differentiated by its quality documentation and impurity controls.
What is the main investment risk in the povidone K90 market?
The main risk is margin compression from supplier competition or raw-material volatility, combined with customer substitution toward lower-cost binders or alternative polymers.
References
-
Ashland Global Holdings Inc. (2024). Annual report 2024. Ashland Global Holdings Inc.
-
BASF SE. (2024). BASF report 2024. BASF SE.
-
European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia, 11th edition. Council of Europe.
-
U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
-
United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.
